Novo Nordisk said its new insulin Tresiba carries about the same risk of serious heart problems as Sanofi’s Lantus but offers significantly lower risk of dangerously low blood sugar in people with Type-2 diabetes.
from WSJ.com: US Business http://ift.tt/2gjwFQL
via IFTTT
No comments:
Post a Comment